Previous 10 | Next 10 |
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional i...
Eyenovia ( NASDAQ: EYEN ) said its treatment MicroLine met the main goal of a phase 3 trial to treat presbyopia (farsightedness). The study called VISION-2 enrolled 140 people and evaluated Eyenovia's 2% pilocarpine micro-array print (MAP) formulation, MicroLine, against...
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progre...
Clinical stage ophthalmic company Eyenovia, Inc. ( NASDAQ: EYEN ) added ~7% pre-market Wednesday after H.C. Wainwright launched its coverage with a Buy recommendation on the prospects of its pipeline that includes the Optejet ocular delivery system. The Optejet device ...
NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional ...
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced they will present at the R.W. ...
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical me...
Eyenovia, Inc. (EYEN) Q2 2022 Earnings Conference Call August 10, 2022 16:30 ET Company Participants Eric Ribner - Investor Relations Sean Ianchulev - Chairman Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Conference Cal...
Eyenovia press release ( NASDAQ: EYEN ): Q2 GAAP EPS of -$0.22 (vs. -$0.19 Y/Y). Shares -0.57% . For further details see: Eyenovia Q2 GAAP loss per share widens
Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi™ NDA resubmission on track for the fourth quarter of 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressing as p...
News, Short Squeeze, Breakout and More Instantly...
Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet ® dispensing technology, following consultation with FDA Chronic dry eye estimated to be a $5 billion global addressable market NEW YORK, July 23, ...
Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, ...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current large...